Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequatelyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapyXx_NEWLINE_xXPatients must have fully recovered from any adverse effects of major surgery (to =< grade 1) at least 14 days prior to registrationXx_NEWLINE_xXPatient must have fully recovered from the effects of prior surgery at least 14 days prior to sub-study registrationXx_NEWLINE_xXPatients should have resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE, version 4.0, grade 1 or lessXx_NEWLINE_xXPatients should have resolution of any toxic effects of prior therapy (except fatigue and alopecia) to NCI CTCAE, version 4.0, grade 1 or less, including immune toxicityXx_NEWLINE_xXPatients must have discontinued radiation therapy prior to registering to Step 2 of the study and recovered from any adverse events associated with treatment; prior surgery must be >= 2 weeks from registration to Step 2 and patients must be fully recovered from post-surgical complicationsXx_NEWLINE_xXPatients who relapse on frontline therapy in phases other than maintenance must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXThe patient must have recovered from effects of surgery, postoperative infection, and other complications within 28 days prior to step 2 registrationXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXRecovery from the effects of prior GBM surgery as defined by the Investigator;Xx_NEWLINE_xXPatients must have received prior therapy other than surgery and must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the defined eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequatelyXx_NEWLINE_xXRecovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapyXx_NEWLINE_xXPrior cancer treatment must be completed at least 28 days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to =< grade 1 or baselineXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior anti-cancer therapyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.Xx_NEWLINE_xXRecovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy to CTCAE v4.03 grade 1, baseline or less, except for alopeciaXx_NEWLINE_xXResolution of all toxic side effects from prior oncology treatmentsXx_NEWLINE_xXPatients must have fully recovered (Eastern Cooperative Oncology Group [ECOG] 0-1) from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXMajor surgery =< 2 weeks prior to registration or who have not recovered from side effects of such therapy; subjects must have recovered from any effects of recent radiotherapy that might confound the safety evaluation of study drugXx_NEWLINE_xXHas recovered from the toxic effects of prior therapy to their clinical baselineXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXRecovered to Grade 1 from the effects (excluding alopecia) of any prior therapy for their malignanciesXx_NEWLINE_xXSubjects must have fully recovered from the acute toxic effects of all prior anti-cancer therapyXx_NEWLINE_xXFailure to have fully recovered (i.e., =< grade 1 toxicity or to patient’s clinical baseline) from the reversible effects of prior chemotherapyXx_NEWLINE_xXPatients must have recovered from effects of recent surgery, radiotherapy, or chemotherapy; they should be free of significant infectionXx_NEWLINE_xXFailure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment.Xx_NEWLINE_xXPatients must have recovered from the effects of any prior chemotherapy, as determined by the treating physician and study team, based in part on organ function defined aboveXx_NEWLINE_xXParticipants must have recovered from any acute toxicity associated with prior therapyXx_NEWLINE_xXPatients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy or radiotherapy prior to entering this studyXx_NEWLINE_xXRecovered from the toxic effects of all prior chemotherapy before entering this studyXx_NEWLINE_xXPatient must have recovered from any toxic effects of previous chemotherapy, targeted therapy or radiotherapy as judged by the investigator to ? grade 1Xx_NEWLINE_xXSubjects must have recovered from major side effects of prior therapies or procedures.Xx_NEWLINE_xXBe fully recovered from major surgery and from the acute toxic effects of prior chemotherapy and radiotherapy. Residual chronic toxicities of prior therapy ? grade 2 (eg, peripheral neuropathy, residual alopecia) are allowed.Xx_NEWLINE_xXHas not fully recovered from any effects of major surgery without significant detectable infection.Xx_NEWLINE_xXResolution of all acute toxic effects of prior therapy or surgical procedures to Grade ?1 (except alopecia).Xx_NEWLINE_xXPatients must have fully recovered from the acute effects of all prior therapy and cannot have evidence of graft-versus-host disease (GVHD)Xx_NEWLINE_xXAll clinically significant toxic effects (except peripheral neuropathy) of prior locoregional therapy, surgery, or other anticancer therapy have resolved to =< CTCAE grade 1Xx_NEWLINE_xXMust have completely recovered or recovered to baseline prior to screening from any prior AEs occurring while receiving prior immunotherapy.Xx_NEWLINE_xXINCLUSION - TREATMENT: Recovered from acute toxic effects of prior chemotherapy at least one week before entering this studyXx_NEWLINE_xXRecovered from the toxic effects of prior therapy to < grade 2 toxicity per NCI CTCAE prior to study registration (except lymphopenia).Xx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.Xx_NEWLINE_xXFailure to have fully recovered (i.e. no toxicities > Grade 1) from the reversible effects of prior chemotherapy.Xx_NEWLINE_xXThe patient must have failed at least one prior therapy besides surgery- radiation or chemotherapy (either cytotoxic or biologic agent)-prior to study registration; patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXAny prior radiation must have been completed at least 7 days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatmentXx_NEWLINE_xXINCLUSION - FUSION: Recovered from acute toxic effects of prior chemotherapy at least one week before entering the studyXx_NEWLINE_xXTREATMENT INCLUSION: Recovered from all acute non-hematologic toxic effects of all prior chemotherapyXx_NEWLINE_xXThe patient must have recovered from the effects of surgery, postoperative infection and other complications before enrollment;Xx_NEWLINE_xXFully recovered from any effects of major surgery, and be free of significant infectionXx_NEWLINE_xXFailure to have fully recovered (ie, > grade 1 toxicity) from the reversible effects of prior chemotherapyXx_NEWLINE_xXHave NO continuing acute toxic effects of any prior therapy, including but not limited to biological therapy, radiotherapy, chemotherapy, or surgical procedures, i.e., all such effects must have resolved to Common Terminology Criteria for Adverse Events (CTCAE, version 4.0) grade =< 1; any other surgery (except biopsies) must have occurred at least 28 days prior to study enrollmentXx_NEWLINE_xXHas not recovered to Grade ?1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy. Note: Subjects with Grade ?2 neuropathy is an exception and may enroll.Xx_NEWLINE_xXFailure to have fully recovered (ie, =< grade 1 toxicity) from the reversible effects of prior chemotherapy, except for laboratory abnormalities which are addressed aboveXx_NEWLINE_xXPrior Therapy- Patients must have fully recovered from the acute toxic effects of all prior anti- cancer chemotherapy and be within the following timelines:Xx_NEWLINE_xXFailure to have fully recovered (i.e., =< grade 1 toxicity) from the reversible effects of prior chemotherapyXx_NEWLINE_xXFailure to recover to =< grade 1 from acute, reversible effects of prior chemotherapy, excluding alopecia regardless of interval since last treatment; (NOTE: patients with residual peripheral neuropathy are allowed)Xx_NEWLINE_xXPatients must be fully recovered from all acute effects of prior surgical interventionXx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: Patients must be fully recovered from all acute effects of prior surgical interventionXx_NEWLINE_xXSubjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met; cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusionXx_NEWLINE_xXHaving received treatment in another clinical study within the 30 days prior to commencing study treatment or having side effects of a prior study drug that are not recovered to grade ? 1 or baseline, except for alopeciaXx_NEWLINE_xXPatients must have received no more than 2 prior chemotherapy regimens and/or focal radiotherapy for their brain tumor and fully recovered from the acute treatment related toxicities of all prior therapies prior to entering this study; for those acute baseline adverse events attributable to prior therapy, patients must meet organ function criteriaXx_NEWLINE_xXHas recovered from the toxic effects of prior therapy to their clinical baselineXx_NEWLINE_xXFully recovered from acute toxic effects of any prior chemotherapy, biological modifiers or radiotherapyXx_NEWLINE_xXAll patients must, in the opinion of the study PI, have sufficiently recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXINCLUSION - TREATMENT: Recovered from the acute toxic effects of all prior chemotherapyXx_NEWLINE_xXPatients must be recovered to grade 1 from the effects (excluding alopecia) of any prior therapy for their malignanciesXx_NEWLINE_xXPatients must be at least 4 weeks from radiation or surgery and recovered from all ill effectsXx_NEWLINE_xXParticipants must have fully recovered from the acute toxic effects of all prior treatment to grade 1 or less, except alopecia and =< grade 2 neuropathy which are allowedXx_NEWLINE_xXPatients who relapse on therapy other than standard ALL maintenance must have fully recovered from the acute toxic effects of all prior anti-cancer therapy, defined as resolution of all such toxicities to ? grade 2 or lower per the inclusion/exclusion criteria prior to entering this studyXx_NEWLINE_xXPatients must have recovered to =< grade 1 or stabilized from the toxic effects of any prior chemotherapy (except alopecia)Xx_NEWLINE_xXPatients who have received chemotherapy or any investigational drug < 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXPrior cancer treatment (systemic therapy or radiation therapy) must be completed at least 3 weeks prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to grade =< 1 or baseline.Xx_NEWLINE_xXSubjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met; cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusionXx_NEWLINE_xXPatient must have recovered from acute toxic effects (? grade 1) of previous cancer treatments prior to enrollmentXx_NEWLINE_xXAll acute toxic effects of any prior antitumor therapy resolved to Grade 1.Xx_NEWLINE_xXResolved acute effects of prior therapyXx_NEWLINE_xXParticipants must have fully recovered from the acute toxic effects of all prior anticancer therapies or must adhere to post-treatment conditions as follows:Xx_NEWLINE_xXPatients must have recovered from the effects of prior therapyXx_NEWLINE_xXPatients who have undergone surgery =< 3 weeks or who have not recovered from side effects of this procedure prior to receiving study drugXx_NEWLINE_xXPatients must have received prior therapy other than surgery and must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, biologic therapy or radiotherapy prior to study entryXx_NEWLINE_xXPatient is currently receiving or has received systemic corticosteroids (=< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment)Xx_NEWLINE_xXRecovered from all acute side-effects (except alopecia) related to previous systemic therapyXx_NEWLINE_xXAnticancer chemotherapy during the study or within 4 weeks of study enrollment; subjects must have recovered from the toxic effects of the previous anti-cancer chemotherapy (with the exception of alopecia); anti-cancer therapy is defined as any\r\nagent or combination of agents with clinically proven anti-tumor activity administered by any route with the purpose of affecting the malignancy, either directly or indirectly, including palliative and therapeutic endpointsXx_NEWLINE_xXAll subjects must, in the opinion of the study PI, have sufficiently recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXNo chemotherapy, radiation, or major surgery within two weeks prior to first dose of study drug and/or recovered from the toxic side effects of that therapy, unless treatment is indicated due to progressive disease.Xx_NEWLINE_xXPatients who have not recovered from side effects of prior systemic therapy prior to cycle 1 day 1Xx_NEWLINE_xXFailure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatmentXx_NEWLINE_xXPatients may have had no more than one prior line of chemotherapy or immunotherapy in the metastatic setting; at least 14 days must have elapsed from the last chemo/immunotherapy administration until the start of protocol treatment, and patients must have recovered from the side effects of any of these agentsXx_NEWLINE_xXRecovery from non-hematologic toxic effects of prior therapy to grade ? 1 (except alopecia) by NCI CTCAE Version 4.03;Xx_NEWLINE_xXPatients must have recovered from effects of recent surgery, radiotherapy, or chemotherapyXx_NEWLINE_xXFailure to have fully recovered (ie, =< grade 1 toxicity) from the reversible effects of prior chemotherapyXx_NEWLINE_xXRecovered to Grade 1 or baseline from all toxic effects of previous therapy (except alopecia or neuropathy).Xx_NEWLINE_xXParticipants must have fully recovered from the acute toxic effects of all prior anticancer treatments prior to study drug administration:Xx_NEWLINE_xXAll subjects must, in the opinion of the study PI, have sufficiently recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXFailure to have fully recovered (i.e., =< grade 1 toxicity) from the reversible effects of prior chemotherapyXx_NEWLINE_xXPatients must have recovered from the toxic effects of prior therapy at the time of initiation of the study drug unless toxicity is stableXx_NEWLINE_xXMust have recovered from adverse effects of any prior surgery, radiotherapy or other antineoplastic therapyXx_NEWLINE_xXPatient must have recovered from the acute toxic effects (? grade 1 CTCAE v.4.0) of previous anti-cancer treatment prior to study enrollment; the only exception is that grade 2 neuropathy is permittedXx_NEWLINE_xXRecovered (i.e., ?Grade 1 nonhematologic toxicity) from the reversible effects of prior anticancer therapy.Xx_NEWLINE_xXPrior cancer treatment must be completed at least 14 days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ?grade 1 or to baseline prior to initiation of that therapy.Xx_NEWLINE_xXSubject who has received radiotherapy <14 days prior to registration, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia).Xx_NEWLINE_xXPatients who have not recovered from the toxic effects of prior chemo- and/or radiation therapy; guidelines for this recovery period are dependent upon the specific therapeutic agent being used:\r\n* Patients who are less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 consecutive scans with disease progression or histopathologic confirmation of recurrent tumor\r\n* Patients who have received chemotherapy or bevacizumab =< 4 weeks (except for nitrosourea [6 weeks] or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide [1 week]) prior to starting the study drug unless patients have recovered from side effects of such therapy\r\n* Patients who have received immunotherapy =< 4 weeks prior to starting the study drug unless patients have recovered from side effects of such therapyXx_NEWLINE_xXPatients may have been previously treated for a plexiform neurofibroma but must have fully recovered from the acute toxic effects of all prior chemotherapy or radiotherapy prior to entering this studyXx_NEWLINE_xXParticipants must have recovered to grade 0 or 1 or pre-treatment baseline from clinically significant toxic effects of prior therapy (including but not limited to exceptions of alopecia, laboratory values listed per inclusion criteria, and lymphopenia which is common after therapy with temozolomide)Xx_NEWLINE_xXIncomplete recovery from acute effects of any surgery prior to treatment.Xx_NEWLINE_xXPatients must have resolution of toxic effects to grade 1 or less from prior therapy (except alopecia)Xx_NEWLINE_xXPatients who have not recovered from the toxic effects of prior chemo- and/or radiation therapy; guidelines for this recovery period are dependent upon the specific therapeutic agent being usedXx_NEWLINE_xXPatients may not have received immunotherapy =< 4 weeks prior to starting the study drug unless patients have recovered from side effects of such therapyXx_NEWLINE_xXPatient is currently receiving or has received systemic corticosteroids =< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatmentXx_NEWLINE_xXCurrently receiving or has received systemic corticosteroids within 4 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment (steroids for endocrine replacement is allowed)Xx_NEWLINE_xXPatients must have recovered from the toxic effects of prior therapy to < grade 2 toxicity per Common Toxicity Criteria (CTC) version 4 (except deep vein thrombosis)Xx_NEWLINE_xXPatients must have recovered from the acute toxic effects of all prior therapy to =< grade 1 before entering this studyXx_NEWLINE_xXRecovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessmentXx_NEWLINE_xXFailure to fully recover (i.e. =< grade 1 adverse event [AE]) from the reversible effects of prior chemotherapyXx_NEWLINE_xXFully recovered from acute, reversible effects of prior therapy regardless of interval since last treatment;\r\n* EXCEPTION: neuropathies – if grade 2 neuropathies have been stable for at least 3 months since completion of prior treatment patient is eligibleXx_NEWLINE_xXPatients must be deemed by the investigators to be fully recovered from both acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapyXx_NEWLINE_xXPatients must have recovered from toxicity of prior therapyXx_NEWLINE_xXAll acute toxic effects of any prior radiotherapy, chemotherapy, experimental drug treatment or surgical procedure must have resolved to grade =< 1, except alopecia (any grade) and peripheral neuropathyXx_NEWLINE_xXMust have completely recovered or recovered to baseline prior to screening from any prior adverse events (AEs) occurring while receiving prior immunotherapy.Xx_NEWLINE_xXRecovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessmentXx_NEWLINE_xXRadiation therapy (within 12 weeks of Study Day 1 or has not recovered from the toxic effects of such therapy).Xx_NEWLINE_xXGliadel® Wafer (within 6 months of Study Day 1, or has not recovered from the toxic effects of such therapy).Xx_NEWLINE_xXImmunotherapeutic agents, vaccines, or monoclonal antibody therapy (within 4 weeks of Study Day 1 or has not recovered from the toxic effects of such cancer therapy).Xx_NEWLINE_xXTemozolomide or other chemotherapy (within 4 weeks of Study Day 1 or 6 weeks for nitrogen mustards, or has not recovered from the toxic effects of such cancer therapy).Xx_NEWLINE_xXSurgical resection of brain tumor (within 4 weeks of Study Day 1 or has not recovered from acute side effects of such therapy except for neurological effects).Xx_NEWLINE_xXRecovered to grade 1 from the effects (excluding alopecia) of any prior therapy for their malignanciesXx_NEWLINE_xXResolution of all acute toxic effects of prior therapy, including radiotherapy to grade ? 1 (except toxicities not considered a safety risk for the patient) and recovery from surgical proceduresXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXMust have recovered from the acute toxic effects of all prior therapy prior to registration for this study to grade 1 or lessXx_NEWLINE_xXFailure to have fully recovered (i.e., =< grade 1 toxicity) from the reversible effects of prior ASCT chemotherapyXx_NEWLINE_xXCERITINIB INCLUSION CRITERIA: Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy, chemotherapy or surgical procedures to CTCAE v4.03 grade =< 1Xx_NEWLINE_xXREGORAFENIB INCLUSION CRITERIA: Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy, chemotherapy or surgical procedures to CTCAE v4.03 grade =< 1Xx_NEWLINE_xXENTRECTINIB INCLUSION CRITERIA: Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy, chemotherapy or surgical procedures to CTCAE v4.03 grade =< 1Xx_NEWLINE_xXSubjects must have recovered from the toxic effects of any prior chemotherapy to < grade 1 (except alopecia)Xx_NEWLINE_xXFailure to have fully recovered (ie, =< grade 1 toxicity) from the reversible effects of prior chemotherapyXx_NEWLINE_xXTreated with immunotherapeutic agents, vaccines, or monoclonal antibody (Mab) therapy within 4 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapyXx_NEWLINE_xXTreated with alkylating agents within 4 weeks (6 weeks for nitrosoureas) before enrollment or treated within 1 week before enrollment with daily or metronomic chemotherapy, unless the patient has recovered from the expected toxic effects of such therapy to their baseline or to grade 1Xx_NEWLINE_xXPrior treatment (non-alkylating agents) within 2 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapyXx_NEWLINE_xXPatient must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, radiotherapy, or surgery prior to study entry.Xx_NEWLINE_xXAll acute toxic effects of any prior treatment have resolved to NCI-CTCAE v 4.0 Grade 1 or less (except alopecia) at the time of signing the Informed Consent Form (ICF)Xx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXSubjects in the combination treatment cohort must not have: a history or evidence of psychiatric, substance abuse, or any other clinically significant disorder; toxic effects of the most recent prior chemotherapy not resolved to grade 1 or less (except alopecia); or expected other cancer therapy while on study with the exception of local radiation to the site of bone or other metastasis for palliative treatment.Xx_NEWLINE_xXPatient must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXMust have recovered from the toxic effects of all prior chemotherapyXx_NEWLINE_xXELIGIBILITY CRITERIA- LYMPHODEPLETION/INFUSION OF tvs-CTL: Must have fully recovered from the acute toxic effects of all prior therapy including chemotherapy, radiotherapy and immunotherapyXx_NEWLINE_xXNot recovered to Grade 1 from adverse effects of prior myeloma therapy or radiotherapy prior to screening.Xx_NEWLINE_xXFailure to have fully recovered (i.e., =< grade 1 toxicity) from the effects of prior chemotherapy regardless of the interval since last treatmentXx_NEWLINE_xXFailure to have fully recovered (ie, =< grade 1 toxicity) from the reversible effects of prior chemotherapyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy or radiation to grade 2 or lessXx_NEWLINE_xXFailure to have fully recovered (i.e., ? grade 1 toxicity) from the reversible effects of prior chemotherapy or endocrine therapy, except for grade 2 or greater anemiaXx_NEWLINE_xXAt the time of registration, patient must have recovered from the toxic effects of prior therapy to no more than grade 1 toxicityXx_NEWLINE_xXPatients must have recovered from the toxic effects of prior therapy to grade 1 or better; patients must be at least 3 weeks form the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy and at least 1 week from the last dose of non-myelosuppressive biologic therapyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy:Xx_NEWLINE_xXPatients must have recovered (to Common Toxicity Criteria [CTC] version [v.]4.0 =< grade 1 unless indicated below) from the acute toxic effects of all prior chemotherapy, immunotherapy prior to entering this study, with the exception of alopecia, weight changes and grade I or II lymphopeniaXx_NEWLINE_xXRadiotherapy less than 2 weeks before the first dose of study treatment or have not recovered from acute toxic effects from radiotherapy.Xx_NEWLINE_xXPatient must, in the opinion of the study principal investigator (PI) or designee, have fully recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment onto this studyXx_NEWLINE_xXMust have recovered from toxic effects of prior chemotherapyXx_NEWLINE_xXTreated with immunotherapeutic agents within 4 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapyXx_NEWLINE_xXPrior chemotherapy (non-alkylating agents) within 2 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapyXx_NEWLINE_xXPatients must have recovered from the acute toxic effects of all prior anticancer chemotherapyXx_NEWLINE_xXPrevious chemotherapy, and/or biological therapy for cancer are permitted provided that the acoustic properties of the tumor were not affected; the subject should have recovered from the effects of these or of any prior surgeryXx_NEWLINE_xXPatients must have recovered from the toxic effects of prior therapyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXPrior Therapy- Patients must have fully recovered from the acute toxic effects of all prior anti- cancer chemotherapy and be within the following timelines:Xx_NEWLINE_xXPatients may be entered if they have received prior radiation therapy involving =< 30% of the bone marrow; any prior radiation therapy must have been administered >= 4 weeks prior to start of study treatment and the patient must be recovered from the acute toxic effects of the treatment prior to start of study treatmentXx_NEWLINE_xXRecovered from effects of any prior surgery or cancer therapyXx_NEWLINE_xXRecovered from reversible toxicities of prior therapyXx_NEWLINE_xXFully recovered from toxicity due to prior therapyXx_NEWLINE_xXPatients must have recovered from the toxic effects of any prior chemotherapy to < grade 2 (except for alopecia)Xx_NEWLINE_xXPatients must have discontinued all previous systemic therapies and recovered from side effects due to systemic treatment for more than 14 days prior to starting on treatmentXx_NEWLINE_xXPatients who have not recovered from side effects of prior anti-cancer treatment to less than or equal to grade 1 toxicity according to Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4 within the following time frames:\r\n* Received previous systemic therapy and has not recovered from side effects for more than 14 days prior to starting on treatment\r\n* Received previous radiation therapy and has not recovered from side effects for more than 14 days prior to starting on treatment\r\n* Received previous biologic therapy and has not recovered from side effects for more than 14 days prior to starting on treatmentXx_NEWLINE_xXRecovered from acute toxic effects of prior chemotherapy at least one week before entering this studyXx_NEWLINE_xXPrior radiation therapy completed >= 4 months, and/or chemotherapy completed >= 1 month before study entry, and patient should have recovered from any adverse effectsXx_NEWLINE_xXNo acute toxic effects from previous treatment superior to grade 1 at the start of the studyXx_NEWLINE_xXPrior radiation therapy is permitted as long as:\r\n* Recovered from the toxic effects of radiation treatment before study entry, except for alopeciaXx_NEWLINE_xXPatients must have been off of cytotoxic, immunosuppressive (except steroids), or targeted therapy for at least 2 weeks prior to entering this study, and have recovered from the toxic effects of that therapy to grade 1 or lessXx_NEWLINE_xXRecent prior therapy: systematic chemotherapy less than 2 weeks prior to infusion; exceptions:\r\n* There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such\r\n* Subjects receiving hydroxyurea or oral maintenance chemotherapy may be enrolled provided there has been no increase in dose for at least 2 weeks prior to starting apheresis or treatment\r\n* Subjects receiving steroid therapy at physiological replacement doses only are allowed provided there has been no increase in dose for at least 2 weeks prior to subject starting apheresis or treatment\r\n* Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met; cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusionXx_NEWLINE_xXPatients must have recovered from the acute treatment related toxicities (defined as =< grade 1) of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXPatients must not have chemotherapy, radiotherapy, chemoembolization, radioembolization, or immunoembolization for their malignancy within 30 days prior to treatment and must have recovered from all side effects of therapeutic and diagnostic interventions except those listed in Appendix B of the study protocol.Xx_NEWLINE_xXHas not recovered from toxic effect of prior therapy to < Grade 1.Xx_NEWLINE_xXRecovered from the acute toxic effects of all prior chemotherapy at least one week and 30 days from prior chemotherapy before entering this studyXx_NEWLINE_xXSubjects must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this studyXx_NEWLINE_xXRecovered from the acute toxic effects of all prior chemotherapy at least 4 weeks before entering this studyXx_NEWLINE_xXGreater than 2 weeks since last treatment (chemotherapy or radiation) provided subject has recovered from side effects of treatment prior to the studyXx_NEWLINE_xXParticipants must have fully recovered from the acute toxic effects of all prior anticancer therapy and must meet the following minimum duration from prior anticancer directed therapy prior to study drug administration. If, after the required time frame, the numerical eligibility criteria are met, eg, blood count criteria, the participant is considered to have recovered adequately:Xx_NEWLINE_xXHave recovered from the effects of any prior radiotherapy or surgery;Xx_NEWLINE_xXHave recovered from the acute effects of any prior systemic therapy.Xx_NEWLINE_xXFailure to have fully recovered (i.e., =< grade 1 toxicity) from the reversible effects of prior chemotherapyXx_NEWLINE_xXResolution of all acute toxic effects of previous anticancer therapyXx_NEWLINE_xXFailure to have fully recovered (that is, less than or equal to [<=] Grade 1 toxicity) from the reversible effects of prior chemotherapy.Xx_NEWLINE_xXRecovery from the effects of prior therapy:Xx_NEWLINE_xXHave recovered from any previous therapy side effects or toxicitiesXx_NEWLINE_xXPatient must have recovered from toxicities incurred as a result of any previous anti-myeloma therapy or recovered to baseline.Xx_NEWLINE_xXFull recovery (< grade 1) from the toxic effects of any earlier intervention and a minimum of 28 days from the administration of any investigational agentXx_NEWLINE_xXResolution of any toxic effects of previous therapiesXx_NEWLINE_xXPatients must have been off chemotherapy for 2 weeks prior to entering this study unless there is evidence of rapidly progressive disease. Patients must have recovered from the toxic effects of prior therapy to grade ?1. The use of hydroxyurea is allowed to control counts up to 24 hrs prior to the start of therapy with AR-67.Xx_NEWLINE_xXRecovered from all acute adverse effects of prior therapies, excluding alopecia (hair loss)Xx_NEWLINE_xXNo chemotherapy, radiation, or major surgery within 2 weeks prior to first dose of study drug and recovered from toxic side effects of that therapy, unless treatment is indicated due to progressive disease.Xx_NEWLINE_xXParticipant must have recovered from the effects of surgery, postoperative infection, and other complications; has no significant post-operative hemorrhage.Xx_NEWLINE_xXAny prior radiation must have been completed at least 7 days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatmentXx_NEWLINE_xXHas not recovered to ? Grade 1 or baseline from toxic effects of prior therapy and/or complications from prior surgical intervention before starting study treatment.Xx_NEWLINE_xXPatient received chemotherapy, surgery, or radiotherapy (for therapeutic purposes) within 3 weeks, monoclonal antibodies or investigational drugs within 4 weeks or tyrosine kinase inhibitor within 1 week, or the patient has not recovered (from grade ?2 side effects of the previous therapy) prior to lymphodepletion regimen. Note: Patient may be still eligible if the patient has not fully recovered from grade ?2 toxicities if accumulated toxicities with the lymphodepletion therapy are not expectedXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.Xx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXPatients must have recovered from side effects resulting from prior cancer-directed therapy to a level of grade 1 or less (unless deemed not clinically significant by study investigator)Xx_NEWLINE_xXFailure to have fully recovered (i.e., ? grade 1 toxicity) from the reversible effects of prior treatment for WMXx_NEWLINE_xXResolution of all acute toxic effects of prior therapy or surgical procedure to grade 1 or baseline prior to randomizationXx_NEWLINE_xXThe subject must have recovered (=< grade 1) from the acute toxic effects of prior therapy\r\n* NOTES: Subjects may have received a single platinum-based cytotoxic chemotherapy regimen; subjects having received prior cytotoxic chemotherapy must have completed their treatment more than 6 months prior to registration; subjects may have received prior therapy with hormones or biologic agents, but such therapies must be discontinued at least 28 days prior to registration for protocol therapyXx_NEWLINE_xXPatients must be at least 4 weeks (28 days) from major surgery and fully recovered from all acute effects of prior surgical interventionXx_NEWLINE_xXSubjects that have not recovered from side effects of previous therapy.Xx_NEWLINE_xXParticipants must have recovered to grade 0 or 1 or pre-treatment baseline from clinically significant toxic effects of prior therapy (including but not limited to exceptions of alopecia, laboratory values listed per inclusion criteria, and lymphopenia which is common after therapy with temozolomide)Xx_NEWLINE_xXPatients must have recovered from the effects of induction, re-induction, or consolidation chemotherapy (all toxicities =< grade I with the exception of reversible electrolyte abnormalities), and have no ongoing active infection requiring treatmentXx_NEWLINE_xXFailure to fully recover from acute, reversible effects of prior anti-cancer therapy regardless of interval since last treatment; NOTE: patients must have fully recovered from all acute, reversible toxicities (defined as Common Terminology Criteria for Adverse Events [CTCAE] 4.0 =< grade 1) associated with previous treatmentXx_NEWLINE_xXFailure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatmentXx_NEWLINE_xXSubjects must have recovered from the toxic effects of any prior chemotherapy to =< grade 1 (except alopecia)Xx_NEWLINE_xXMost recent PD-1 or PD-L1 inhibitor infusion must be completed at least 6 weeks of randomization. The subject must have recovered from all reversible acute toxic effects (other than alopecia) to =< grade 1 or baseline.Xx_NEWLINE_xXPatients must have recovered from the toxic effects of prior therapies (=< grade 1)Xx_NEWLINE_xXPatients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, stem cell transplant or radiotherapy prior to entering this study; all prior treatment-related toxicities must have resolved to =< grade 2 prior to enrollmentXx_NEWLINE_xXFailure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatmentXx_NEWLINE_xXFailure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatmentXx_NEWLINE_xXPatients must have recovered from toxicity of prior therapyXx_NEWLINE_xXFailure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatmentXx_NEWLINE_xXPatients must have fully recovered from major surgery and from the acute toxic effects of prior chemotherapy and radiotherapy (residual grade 1 toxicity, e.g., grade 1 peripheral neuropathy, and residual alopecia are allowed)Xx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study enrollmentXx_NEWLINE_xXDiscontinuation of other therapies (except corticosteroids) for the treatment of NF2\n             and resolution of any acute toxic effects of prior therapiesXx_NEWLINE_xXPatients must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or investigational drug) within 21 days prior to Step 2 re-registration; patients must have recovered (=< grade 1) from any side effects of prior therapyXx_NEWLINE_xXAt least 3 weeks should have elapsed since the last treatment (e.g. chemotherapy, targeted small molecule therapy, immunotherapy or radiation) and must have recovered to grade 1 or better from the acute effects of prior therapyXx_NEWLINE_xXPatients must have fully recovered from major surgery and from the acute toxic effects of prior chemotherapy and radiotherapy - residual grade 1 toxicity, e.g., grade 1 peripheral neuropathy and residual alopecia are allowedXx_NEWLINE_xXPatients must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or investigational drug) within 21 days prior to re-registration; patients must have recovered (=< grade 1) from any side effects of prior therapyXx_NEWLINE_xXPatients must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or investigational drug) within 21 days prior to step 2 re-registration; patients must have recovered (< grade 1) from any side effects of prior therapyXx_NEWLINE_xXPatient has not recovered to grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapyXx_NEWLINE_xXPatient is currently receiving or has received systemic corticosteroids =< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatmentXx_NEWLINE_xXAt least 3 weeks must have elapsed from any prior chemotherapy, and the patient must have recovered from side effects to =< grade 1 toxicitiesXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXPatients who relapse on therapy other than standard ALL maintenance therapy must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXPatients who have not recovered to grade =< 1 or to their baseline from clinically significant adverse effectsXx_NEWLINE_xXSubject is currently receiving or has received systemic corticosteroids =< 2 weeks prior to starting study drug or who have not fully recovered from side effects of such treatmentXx_NEWLINE_xXAll patients must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapyXx_NEWLINE_xXAt least 3 weeks has elapsed from any prior therapy, and the patient has recovered from side effects to =< grade 1 toxicities per Common Toxicity Criteria (CTC)Xx_NEWLINE_xXFailure to have fully recovered (i.e., =< grade 1 toxicity) from the reversible effects of prior chemotherapy, excluding alopeciaXx_NEWLINE_xXRecovered from the toxic effects of all prior chemotherapyXx_NEWLINE_xXSubjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met; cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusionXx_NEWLINE_xXPatients must be recovered from both the acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapyXx_NEWLINE_xXPatients must be recovered from both the acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapyXx_NEWLINE_xXFailure to fully recover from acute, reversible effects of prior chemotherapy (other anti-neoplastic therapy) and radiation therapyXx_NEWLINE_xXRecovered from the acute toxic effects of all prior chemotherapy at least a week before entering this studyXx_NEWLINE_xXRecovered from the toxic effects of all prior chemotherapy before entering this studyXx_NEWLINE_xXPatients must have recovered from effects of recent surgery, radiotherapy or chemotherapyXx_NEWLINE_xXRecovery from the adverse effects ? grade 1;Xx_NEWLINE_xXSubject has recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to first dose. All prior treatment-related toxicities must have resolved to ? Grade 2 prior to enrollment.Xx_NEWLINE_xXSubjects must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer.Xx_NEWLINE_xXLack of recovery from toxic effects of previous treatment for RCC ? grade 1 with the exception of alopecia, unless stabilized under adequate medical control.Xx_NEWLINE_xXdiscontinued previous localized radiotherapy for palliative purposes or for lytic lesions at risk of fracture at least 2 weeks prior to randomization and recovered from the acute effects of therapyXx_NEWLINE_xXPatient must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancerXx_NEWLINE_xXPRIOR/CONCURRENT THERAPY CRITERIA: Patients must have recovered from any adverse effects from prior therapy (except alopecia) to =< CTCAE grade 1 prior to registrationXx_NEWLINE_xXMust have recovered (ie, ? Grade 1 toxicity or participant's baseline status) from the reversible effects of prior therapyXx_NEWLINE_xXPatients who have received any antineoplastic therapy > 28 days prior to starting treatment with ABC294640 and have not adequately recovered from side effects and toxicities of previous antineoplastic therapy.Xx_NEWLINE_xXPatients not recovered to Grade 1 or stabilized from the effects (excluding alopecia) of any prior therapy for their malignanciesXx_NEWLINE_xXHas not recovered to ? Grade 1 from toxic effects of prior therapy.Xx_NEWLINE_xXResolution of all acute toxic effects of prior anti cancer therapy or surgical procedures to NCI CTCAE version 4.0 Grade ?1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).Xx_NEWLINE_xXHas not recovered from toxic effects of prior therapy to ? Grade 1.Xx_NEWLINE_xXRecovery from the toxic effects of prior therapy, with a minimum time of:Xx_NEWLINE_xXHave recovered from any acute toxicity related to prior therapy.Xx_NEWLINE_xXAll acute toxic effects of any prior antitumor therapy resolved to Grade ? 1 before the start of study drugXx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to first dose of study drug, or has not recovered from adverse effects due to a previously-administered agentXx_NEWLINE_xXParticipant must have resolution to Grade 1 or lower of any toxic effects (excepting alopecia) of the most recent therapy prior to Cycle 1 Day 2.Xx_NEWLINE_xXResolution of all clinically relevant acute non-hematologic toxic effects of any prior antitumor therapy resolved to Grade <=1Xx_NEWLINE_xXPatients must have recovered from any acute toxicity associated with prior therapy by the start of study treatmentXx_NEWLINE_xXFailure to fully recover from acute, reversible effects of prior chemotherapy (other anti-neoplastic therapy) and radiation therapy to adverse event severity of =< grade 1Xx_NEWLINE_xXResolved acute effects of any prior therapy to baseline or Grade ?1Xx_NEWLINE_xXPatients must have recovered (to baseline/stabilization) from prior therapy-associated acute toxicities.Xx_NEWLINE_xXPatient must have recovered from the acute toxic effects of the treatment before beginning study therapy.Xx_NEWLINE_xXResolution of any toxic effects (excepting alopecia) of the most recent therapyXx_NEWLINE_xXAdverse effects due to prior therapy unresolved at randomizationXx_NEWLINE_xXPrevious chemotherapy for local recurrence is allowed but must have been discontinued at least 4 weeks before receiving the study drug and the patient must have recovered from acute adverse effectsXx_NEWLINE_xXPrevious radiation therapy was allowed but must have been discontinued at least 2 months before study drug is administered, and the patient must have recovered from acute toxic effectsXx_NEWLINE_xXRadiation therapy completed at least 7 days prior to start of study treatment and patients must have recovered from any acute adverse effects.Xx_NEWLINE_xXPatients must have recovered from the toxic effects of prior therapiesXx_NEWLINE_xXPatients must have fully recovered from major surgery and from the acute toxic effects of prior chemotherapy and radiotherapy (residual grade 1 toxicity, e.g. grade 1 peripheral neuropathy, and residual alopecia are allowed)Xx_NEWLINE_xXHave discontinued previous localized radiotherapy for palliative purposes or for lytic lesions at risk of fracture prior to randomization and recovered from the acute effects of therapyXx_NEWLINE_xXResolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (Parts 1A and 1B) and/or recovered from major surgery or radiation therapyXx_NEWLINE_xXFailure to have fully recovered (i.e., =< grade 1 toxicity) from the reversible effects of prior chemotherapyXx_NEWLINE_xXPatients who have not recovered from symptomatic side effects of radiotherapy at the time of initiation of screening procedure.Xx_NEWLINE_xXPrior systemic therapy within 14 days of study enrollment; patients must be adequately recovered from prior systemic therapy side effects as deemed by the treating investigatorXx_NEWLINE_xXRecovered from acute toxic effects of all prior chemotherapy at least one week and 30 days from prior chemotherapy before entering this studyXx_NEWLINE_xXSubjects must have recovered from the toxic effects of prior therapy; residual toxicity from any previous treatment must be =< Grade 1Xx_NEWLINE_xXFailure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatmentXx_NEWLINE_xXHas not recovered to ? Grade 1 from toxic effects of previous therapy and/or complications from previous surgical intervention before starting study therapy.Xx_NEWLINE_xXPatient is currently receiving or has received systemic corticosteroids =< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatmentXx_NEWLINE_xXSubjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior system anticancer therapy, radiotherapy or surgery.Xx_NEWLINE_xXRecovered from toxic effects attributed to UC-961 to grade 1 levels, or baselineXx_NEWLINE_xXPatient has not recovered to grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapyXx_NEWLINE_xXFailure to have fully recovered (ie, =< grade 1 toxicity) from the reversible effects of prior chemotherapyXx_NEWLINE_xXParticipant has not recovered from the acute toxic effects of prior anticancer therapy, radiation, or major surgery/significant trauma.Xx_NEWLINE_xXFailure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatmentXx_NEWLINE_xXPatients must have recovered from side effects from prior cancer-directed therapy to grade 1 or less (unless deemed not clinically significant by study investigator)Xx_NEWLINE_xXTreatment with any investigational agent within 28 days prior to registration for protocol therapy and the subject must have recovered from the acute toxic effects of the regimen.Xx_NEWLINE_xXParticipants must have recovered to grade 0 or 1 or pre-treatment baseline from clinically significant toxic effects of prior therapy (including but not limited to exceptions of alopecia, laboratory values listed per inclusion criteria, and lymphopenia which is common after therapy with temozolomide)Xx_NEWLINE_xXFailure to fully recover from side effects of prior therapy or surgeryXx_NEWLINE_xXPatient who has not recovered to grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapyXx_NEWLINE_xXHistory of prior malignancy, except for conditions as listed in the protocol if patients have recovered from the acute side effects incurred as a result of previous therapyXx_NEWLINE_xXFailure to recover to grade =< 1 from acute, reversible effects of prior chemotherapy regardless of interval since last treatmentXx_NEWLINE_xXFailure to recover from the reversible effects of prior anticancer therapies with the exception of alopecia, and after-effects associated with prior tyrosine kinase inhibitor therapy such as hair depigmentation, hypothyroidism, and/or splinter hemorrhage.Xx_NEWLINE_xXPatients must have recovered from toxicity of prior therapyXx_NEWLINE_xXFailure to have fully recovered (ie, =< grade 1 toxicity) from the reversible effects of prior chemotherapyXx_NEWLINE_xXSubjects may have been previously treated for a plexiform neurofibroma or other tumor/malignancy, but must have fully recovered from the acute toxic effects of all prior chemotherapy or radiotherapy prior to entering this studyXx_NEWLINE_xXSubjects must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer. (For example, subjects with residual Grade 1 toxicity or stable Grade 2 peripheral neuropathy due to prior chemotherapy are allowed with approval of the Medical Monitor.)Xx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy (toxicity < grade 2)Xx_NEWLINE_xXThe patient has not recovered from the acute toxic effects of prior chemotherapy, radiation, or major surgery/significant trauma.Xx_NEWLINE_xXSubjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment.Xx_NEWLINE_xXResolved acute effects of prior therapyXx_NEWLINE_xXParticipants must have fully recovered from the acute toxic effects of all prior anti-cancer therapyXx_NEWLINE_xXResolution of all acute toxic effects of prior therapy or surgical procedure to Grade <= 1 or baseline prior to randomizationXx_NEWLINE_xXFailed to have recovered from the reversible effects of previous anticancer therapiesXx_NEWLINE_xXFully recovered from acute toxic effects of any prior chemotherapy, biological modifiers or radiotherapyXx_NEWLINE_xXAt the time of registration, patient must have recovered from the toxic effects of prior therapy to no more than grade 1 toxicityXx_NEWLINE_xXNo acute toxic effects from previous treatment superior to grade 1 at the start of the studyXx_NEWLINE_xXAll acute toxic effects of any prior treatment have resolved to NCI-CTCAE v4.0 Grade 1 or less at the time of signing the Informed Consent Form (ICF).Xx_NEWLINE_xXPatients must have recovered from any reversible effects of prior therapies to no more than grade 1 toxicity, with the exception of alopeciaXx_NEWLINE_xXThe patient must have recovered from the effects of surgery, post-operative infection, and other complications before study registration.Xx_NEWLINE_xXAt least 4 weeks and recovery to grade 0-1 from reversible effects or prior surgery (i.e., incisional pain, wound drainage)Xx_NEWLINE_xXFailure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatmentXx_NEWLINE_xXMust have recovered from acute toxicity from prior treatmentXx_NEWLINE_xXPatients must have recovered from the toxic effects of all prior therapy before entering this studyXx_NEWLINE_xXPatients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study; no chemotherapy or radiotherapy may be given within 2 weeks prior to the start of protocol treatmentXx_NEWLINE_xXPatients must have recovered from all prior therapyXx_NEWLINE_xXPatients must have been off chemotherapy for 2 weeks prior to entering this study, unless there is evidence of rapidly progressive disease, and must have recovered from the toxic effects of that therapy to at least grade 1. Use of hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy.Xx_NEWLINE_xXDiscontinued all prior cancer treatments for cancer & recovered from the acute effects of therapyXx_NEWLINE_xXFailure to have fully recovered (ie, Grade 1 toxicity) from the effects of prior chemotherapy (except for alopecia) regardless of the interval since last treatment.Xx_NEWLINE_xXNo prior therapy for recurrent ALL is allowed prior to study entry with the exception of intrathecal (IT) chemotherapy; participants who have relapsed while receiving up-front therapy are eligible, but must have recovered from adverse effects from any previously administered agentsXx_NEWLINE_xXThe patient has recovered from reversible toxicity from prior therapy. Permanent and stable side effects or changes are acceptable if ? Grade 1 (CTCAE, v4.03)Xx_NEWLINE_xXPatients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiation therapy prior to entry on study; patients must have had at least one prior treatment regimen; patients may have received treatment previously with cyclophosphamide topotecan or bevacizumabXx_NEWLINE_xXRecovered (i.e., < grade 1 toxicity) from the reversible effects of prior antineoplastic therapyXx_NEWLINE_xXResolution of all acute toxic effects of any prior treatments to NCI CTC (Version 3.0) grade <=1Xx_NEWLINE_xXRecovered from effects of recent surgery, radiotherapy, or chemotherapyXx_NEWLINE_xXPatients must have had no chemotherapy, radiotherapy, or biologic therapy for their malignancy in the month prior to treatment and must have recovered from all side effects of therapeutic and diagnostic interventionsXx_NEWLINE_xXParticipants must have recovered from the acute effects of chemotherapy and radiotherapy and from surgical side effects following definitive breast surgery.Xx_NEWLINE_xXFailure to have fully recovered from the reversible effects of prior anti-cancer therapyXx_NEWLINE_xXResolution of all acute toxic effects of any prior treatments to NCI CTC (Version 3.0) grade <=1Xx_NEWLINE_xXPatients may be treated on this trial without having received prior therapy; if patients have received prior therapy, they must have recovered from all toxic effects prior to entering this studyXx_NEWLINE_xXSubjects who have not recovered from the effects of recent surgeryXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiation therapy prior to entering this studyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.Xx_NEWLINE_xXResolution to Grade ? 1 Adverse Events, of all clinically significant toxic effects of prior therapyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.Xx_NEWLINE_xXHistory of severe side effects toimmunotherapyXx_NEWLINE_xXRecovered from all toxic effects (excluding alopecia) of any prior anti-cancer therapy to Grade ? 1 or to the baseline laboratory values.Xx_NEWLINE_xXPatients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy, up to CTCAE grade 1Xx_NEWLINE_xXFailure to have fully recovered (i.e., =< grade 1 toxicity) from the reversible effects of prior chemotherapy, radiation therapy or targeted therapyXx_NEWLINE_xXHas recovered (ie, <= Grade 1 toxicity or eligibility per this protocol is met) from the reversible effects of prior anticancer therapy.Xx_NEWLINE_xXChemotherapy < 2 weeks prior to starting study drug with the following exception: There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of suchXx_NEWLINE_xXFailure to have fully recovered (ie, =< grade 1 toxicity) from the reversible effects of prior chemotherapyXx_NEWLINE_xXFailure to have fully recovered (i.e., =< grade 1 toxicity) from the reversible effects of prior chemotherapyXx_NEWLINE_xXare recovered from the acute adverse effects of prior therapies (excluding alopecia and Grade ?2 neuropathy).Xx_NEWLINE_xXPatients must have received prior therapy other than surgery and must have fully recovered from the acute treatment related toxicities of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXPrior therapy: \r\n* The patient’s malignancy must have relapsed after or failed to respond to frontline curative therapy and/or there must not be any potentially curative treatment options available at the time of study entry\r\n* There is no limit to the number of prior treatment regimens; however, patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study enrollment; acute toxicity of any previous therapy must have resolved to grade 1 or less, unless specified elsewhereXx_NEWLINE_xXReceived radiation (including therapeutic radioisotopes such as strontium 89) therapy ? 3 months prior to the first dose of study treatment and have not recovered from side effects of such therapy (? Grade 1) prior to the first dose of study treatment, except for alopecia.Xx_NEWLINE_xXPatient has not recovered to ? grade 1 (except alopecia) from related side effects of any prior antineoplastic therapyXx_NEWLINE_xXRecovered (=< grade 1 toxicity) from the reversible effects of prior antineoplastic therapyXx_NEWLINE_xXPatient must have recovered sufficiently from any adverse effects of neoadjuvant treatmentXx_NEWLINE_xXPatient must have recovered sufficiently from any adverse effects of neoadjuvant treatmentXx_NEWLINE_xXPatients must have recovered from the toxic effects of all prior chemotherapy before entering this studyXx_NEWLINE_xXThe patient must have discontinued all previous therapies for acute leukemia for at least 14 days and recovered from the acute non-hematologic side effects of the therapyXx_NEWLINE_xXParticipants must have fully recovered from the acute toxic effects of all prior therapy prior to first administration of study drugXx_NEWLINE_xXPatients must be recovered from acute and late effects of any prior surgery, radiotherapy or other anti-neoplastic therapyXx_NEWLINE_xXSubjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior systemic anticancer therapy, radiotherapy or surgeryXx_NEWLINE_xXHas not recovered from toxic effect of prior therapy to < Grade 1.Xx_NEWLINE_xXPatients must have recovered from the effects of prior surgery.Xx_NEWLINE_xXHave discontinued all previous cancer therapies and any agents that have not received regulatory approval for any indication, for at least 21 days or 5 halflives prior to study enrollment, whichever is shorter, and recovered from the acute effects for therapy.Xx_NEWLINE_xXResolution of all acute toxic effects of prior chemotherapy, and other cancer treatmentsXx_NEWLINE_xXRecovered from the effects of any prior systemic therapy, radiotherapy or surgeryXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior anticancer chemotherapyXx_NEWLINE_xXMust have recovered from all side effects of their most recent systemic or local treatmentXx_NEWLINE_xXPRIOR THERAPY Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.Xx_NEWLINE_xXPersistent toxic effects with severity of CTCAE grade 2 or greater (excluding alopecia) caused by previous treatmentXx_NEWLINE_xXPatients must have recovered from side effects from prior cancer-directed therapy to grade 1 or less (unless deemed not clinically significant by study investigator)Xx_NEWLINE_xXAll acute toxic effects of any prior antitumor therapy resolved to Grade ? 1 before enrollment, with the exception of alopecia (any grade permitted)Xx_NEWLINE_xXParticipants who have not recovered from any reversible side effects (except alopecia) to Grade 0 or 1 toxicity attributed to the administration of an investigational therapeutic agent, chemotherapy, immunotherapy, radiotherapy, or other agents previously used to treat the cancer.Xx_NEWLINE_xXPatients who have not recovered from symptomatic side effects of radiotherapy at the time of initiation of screening procedure.Xx_NEWLINE_xXSubject has not fully recovered from the acute toxicities (except alopecia) of any prior anti-cancer therapy.Xx_NEWLINE_xXPatient has not recovered from the acute toxic effects of prior anticancer therapy, radiation, or major surgery/significant trauma.Xx_NEWLINE_xXSystemic treatments: Must have discontinued previous systemic treatments for cancer and recovered from the acute effects of therapy. Participants must have discontinued:Xx_NEWLINE_xXRecovered from the reversible effects of prior antineoplastic therapy (ie, ? Grade 1 toxicity or baseline).Xx_NEWLINE_xXPrior Therapy: Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. Myelosuppressive Chemotherapy:Xx_NEWLINE_xXRecovered (that is, less than or equal to (<=) Grade 1 toxicity) from the effects of prior antineoplastic therapy.Xx_NEWLINE_xXUse of an investigational agent that is not expected to be cleared by the time of first dose of study drug or that has been demonstrated to have prolonged side effects. Patients must have recovered from all side effects to a Grade 0 or 1 (except alopecia and neuropathy).Xx_NEWLINE_xXRecovery from the effects of surgery.Xx_NEWLINE_xXHave discontinued previous treatments for cancer and recovered from all acute toxic effects of prior systemic therapy (except alopecia) to grade ?1;Xx_NEWLINE_xXResolution of acute toxic effects of prior chemotherapy and other cancer treatmentsXx_NEWLINE_xXRecovered from effects of recent surgery, radiotherapy, and chemotherapyXx_NEWLINE_xXRecovery from the toxic effects of prior therapy to not more than grade 1 or > 3 weeks from prior therapy to registration, whichever is laterXx_NEWLINE_xXPatients must have fully recovered from any effects of major surgery, and be free of significant detectable infectionXx_NEWLINE_xXPatients must be recovered from the effects of any prior surgery, radiotherapy, or other antineoplastic therapyXx_NEWLINE_xXAcute toxic effects of previous anticancer chemotherapy or immunotherapy have to be normalized to CTCAE Grade equal or lower than 1 (excluding alopecia)Xx_NEWLINE_xXFailure to fully recover from acute, reversible effects of prior surgery or chemotherapy regardless of interval since last treatmentXx_NEWLINE_xXRecovered from the effects of prior antineoplastic therapyXx_NEWLINE_xXPatients must have recovered from all acute adverse effects (excluding alopecia) of prior therapies to baseline or <= grade 1 prior to study entry.Xx_NEWLINE_xXFailure to have recovered from clinically significant effects of prior chemotherapy (defined as toxicity greater than Grade 1 with the exception of alopecia)Xx_NEWLINE_xXRecovered (i.e., =< grade 1 toxicity) from the reversible effects of prior antineoplastic therapyXx_NEWLINE_xXPatients who have received targeted therapy (e.g. sunitinib, sorafenib, pazopanib) =< 1 week prior to starting study drug, or who have not recovered from the side effects of such therapyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy prior to study enrollment.Xx_NEWLINE_xXHas not recovered to ? Grade 1 from toxic effects of prior therapy.Xx_NEWLINE_xXPatients must have been off all prior therapy for leukemia except hydroxyurea for 1 week prior to entering this study and recovered from the toxic effects of that therapyXx_NEWLINE_xXPatients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy. Up to CTCAE Grade 1 is acceptable for patients with known peripheral neuropathyXx_NEWLINE_xXPatients must have recovered from any previous therapy side effects or toxicities prior to initiating protocol study infusions.Xx_NEWLINE_xXParticipants must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyXx_NEWLINE_xXPatients must have recovered from toxicity of prior therapyXx_NEWLINE_xXPatient has received other investigational drugs within 14 days before enrollment or who have not recovered from side effects of those therapiesXx_NEWLINE_xXResolution to Grade ? 1 Adverse Events, of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (except alopecia)Xx_NEWLINE_xXAll patients must be off previous chemo- and/or radiotherapy for at least three (3) weeks prior to entrance into the study and have recovered from any toxic effects induced by such treatment(s). Patients who have received a nitrosourea type drug must have had no treatment within the last six weeks.Xx_NEWLINE_xXPrior cancer treatment must be completed at least 14 days prior to registration for protocol therapy and the patient must have recovered from the acute toxic effects of the regimen. With the exception of Bevacizumab treatment, which must be completed 30 days prior to registration for protocol therapy.Xx_NEWLINE_xXPrior/Concurrent Therapy: Research participants must have recovered from the acute effects of prior treatment and:Xx_NEWLINE_xXPrevious chemotherapy, and/or biological therapy for cancer are permitted provided that the acoustic properties of the tumor were not affected, but the subject should have recovered from the effects of these or of any prior surgeryXx_NEWLINE_xXReceived the last administration of nitrosourea or mitomycin-C =< 42 days prior to study registration, or who have not recovered from the side effects of such therapyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study; at least 14 days must have elapsed from prior chemotherapy; at least 7 days must have elapsed since receiving biological therapyXx_NEWLINE_xXHave not recovered from the adverse effects or toxicities of lymphoma therapy most recently administeredXx_NEWLINE_xXPatients must have fully recovered from the acute effects of all prior therapyXx_NEWLINE_xXRecovered (that is, <= Grade 1 toxicity) from the reversible effects of prior anticancer therapy.Xx_NEWLINE_xXPatients having undergone recent resection (within 5 weeks prior to registration) of their glioblastoma to treat current recurrence prior to study treatment must have recovered from the effects of surgery (including patient's skin having fully recovered from the surgical wound) Note: a 4-week window is required after surgery prior to starting treatment. For CNS-related stereotactic biopsies, a minimum of 7 days must have elapsed prior to registration.Xx_NEWLINE_xXPatients must have recovered from the toxic effects of prior therapy at the time of registration as follows:Xx_NEWLINE_xXParticipants who have had radiotherapy within 4 weeks prior to entering the study or those who have not recovered from gastrointestinal (GI) adverse events due to induction therapy; patients who have had localized radiation which would not result in any GI effects are allowed on studyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy prior to entering study; three (3) weeks must have elapsed since the administration of prior chemotherapyXx_NEWLINE_xXPatients must have completed mastectomy or breast-sparing surgery and must have recovered from all side effects of the surgery; if patients were treated with chemotherapy and/or radiation therapy, these treatments must be completed at least 28 days prior to study registration; patients should have recovered from all grade 2 or higher side effects of chemotherapy and/or radiation therapy with the exception of alopecia and peripheral neuropathy; concurrent bisphosphonate and trastuzumab therapies are allowedXx_NEWLINE_xXRecovered from the effects of any prior surgery or radiotherapyXx_NEWLINE_xXDiseases refractory/relapsed after one or more systemic cytotoxic therapies; patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.Xx_NEWLINE_xXRecovered from the reversible effects of prior antineoplastic therapy (with the exception of alopecia and Grade 1 neuropathy).Xx_NEWLINE_xXResolution of all clinically significant toxic effects of prior therapy.Xx_NEWLINE_xXPatient has recovered from the toxic effects of prior therapy, and is at least 30 days from the most recent cytotoxic therapy, prior to enrollmentXx_NEWLINE_xXAnti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the effects of prior chemotherapy (hematological and bone marrow suppression effects).Xx_NEWLINE_xXAnti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the effects of prior chemotherapy (hematological and bone marrow suppression effects).Xx_NEWLINE_xXAt the time of registration, subjects must have recovered from the toxic effects of previous treatments, as determined by the treating physician.Xx_NEWLINE_xXPatients who are currently part of any clinical investigation or who has not had resolution of all acute toxic effects or prior anti-cancer therapy to NCI CTCAE version 4.03 Grade 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).Xx_NEWLINE_xXPatients who have received prior adjuvant high dose interferon are allowed to participate as long as the last injection was given at least 30 days prior to the C11-AMT PET scan and they have fully recovered from side effects (i.e., grade =< 1 or permanent side effects that require hormone replacement therapy)Xx_NEWLINE_xXPatient must have fully recovered from the acute toxic effects of all prior chemotherapy or radiation prior to entering this studyXx_NEWLINE_xXResidual side effects to previous therapy over specific grade prior to initiation of therapyXx_NEWLINE_xXFailure to have fully recovered (ie, =< grade 1 toxicity) from the reversible effects of prior chemotherapyXx_NEWLINE_xXRecovered (that is, grade less than or equal to [<=] 1 toxicity) from the reversible effects of prior anticancer therapy.Xx_NEWLINE_xXRecovered (that is, less than or equal to [<=] Grade 1 toxicity) from the reversible effects of prior anticancer therapy.Xx_NEWLINE_xXPrior therapy: Must have recovered from acute toxic effects of prior anti-cancer therapy (durations relative to date of enrollment):Xx_NEWLINE_xXRecovered (that is, less than or equal to (<=) Grade 1 toxicity) from the effects of prior antineoplastic therapy.Xx_NEWLINE_xXPregnant or breastfeeding (due to toxic effects from tobacco products).Xx_NEWLINE_xXPatients must have completed all previous anticancer therapy for at least 2 weeks prior to the first planned dose of omacetaxine, except as noted below, and must have fully recovered from side effects of a previous therapy.Xx_NEWLINE_xXHas not recovered to ? Grade 1 from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting therapy.Xx_NEWLINE_xXRecovered (that is, <=Grade 1 toxicity) from the reversible effects of prior anticancer therapy.Xx_NEWLINE_xXHave discontinued all previous treatments for cancer and recovered from the acute effects of therapy.Xx_NEWLINE_xXHas not recovered to ? Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapyXx_NEWLINE_xX